ArticleArchives of endocrinology and metabolism2026
Age-related changes in METS-IR and HOMA-IR in obese adults and their relationship with cardiometabolic comorbidities.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInsulin resistance (IR) is central to cardiometabolic risk in obesity, but the clinical utility of IR indices may vary by age. We compared homeostasis model assessment for insulin resistance (HOMA-IR) and metabolic score for insulin resistance (METS-IR) across age groups in obese adults and examined comorbidity burden and discriminatory performance for type 2 diabetes mellitus (T2DM) and hypertension (HT). SUBJECTS AND
methodsThis retrospective, single-center study included adults with a BMI ≥ 30 kg/m2 (n = 481) across four age strata (18-40, 40-65, 65-75, and ≥75 years). Spearman correlation assessed the association between HOMA-IR and METS-IR. Comorbidity burden (0-3 chronic conditions) was modeled using ordinal logistic regression per 1-SD increase in z-scores, adjusted for age, sex, and BMI. Receiver operating characteristic analysis and multivariable logistic regression assessed T2DM and HT.
resultsHOMA-IR and METS-IR were moderately correlated (ρ = 0.342 and p < 0.001, respectively). METS-IR was associated with comorbidity burden (adjusted odds ratio [OR] 1.84; 95% confidence interval [CI] 1.26-2.69; p < 0.01), whereas HOMA-IR was not (OR 1.12; 95% CI 0.92-1.36; p = 0.256). Discriminatory performance was limited for T2DM (area under curve [AUC] 0.500 vs. 0.537) and HT (AUC 0.471 vs. 0.519). METS-IR remained associated with T2DM (OR 2.51; 95% CI 1.60-3.93; p < 0.001) and HT (OR 1.81; 95% CI 1.13-2.91; p < 0.05).
conclusionIn obese adults, METS-IR demonstrated a stronger association with comorbidity burden than HOMA-IR. However, because both indices showed limited discriminatory performance for T2DM and HT, they should not be used as standalone tools for treatment guidance or diagnostic classification. Rather, they should be interpreted alongside age, clinical, and biochemical findings, as isolated use may be misleading and fail to identify disease in specific patient subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.